ATE526958T1 - Acetyl-l-carnitin für die vorbeugung und/oder behandlung von peripheren neuropathien hervorgerufen durch thalidomid - Google Patents

Acetyl-l-carnitin für die vorbeugung und/oder behandlung von peripheren neuropathien hervorgerufen durch thalidomid

Info

Publication number
ATE526958T1
ATE526958T1 AT03775788T AT03775788T ATE526958T1 AT E526958 T1 ATE526958 T1 AT E526958T1 AT 03775788 T AT03775788 T AT 03775788T AT 03775788 T AT03775788 T AT 03775788T AT E526958 T1 ATE526958 T1 AT E526958T1
Authority
AT
Austria
Prior art keywords
thalidomide
carnitine
acetyl
prevention
treatment
Prior art date
Application number
AT03775788T
Other languages
English (en)
Inventor
C Cavazza
C Pisano
L Vesci
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE526958T1 publication Critical patent/ATE526958T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03775788T 2002-11-13 2003-10-23 Acetyl-l-carnitin für die vorbeugung und/oder behandlung von peripheren neuropathien hervorgerufen durch thalidomid ATE526958T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/292,823 US20030199535A1 (en) 1998-07-30 2002-11-13 Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
PCT/IT2003/000656 WO2004043454A1 (en) 2002-11-13 2003-10-23 Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents

Publications (1)

Publication Number Publication Date
ATE526958T1 true ATE526958T1 (de) 2011-10-15

Family

ID=32312146

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03775788T ATE526958T1 (de) 2002-11-13 2003-10-23 Acetyl-l-carnitin für die vorbeugung und/oder behandlung von peripheren neuropathien hervorgerufen durch thalidomid

Country Status (19)

Country Link
US (2) US20030199535A1 (de)
EP (1) EP1562577B1 (de)
JP (1) JP2006508958A (de)
KR (1) KR20050075012A (de)
CN (1) CN1708297A (de)
AR (1) AR041947A1 (de)
AT (1) ATE526958T1 (de)
AU (2) AU2003283807B2 (de)
BR (1) BR0316131A (de)
CA (1) CA2505937C (de)
CY (1) CY1112399T1 (de)
DK (1) DK1562577T3 (de)
ES (1) ES2374503T3 (de)
MX (1) MXPA05004752A (de)
PL (1) PL379244A1 (de)
PT (1) PT1562577E (de)
SI (1) SI1562577T1 (de)
TW (1) TWI362260B (de)
WO (1) WO2004043454A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002313817A1 (en) * 2001-08-27 2003-03-10 Advanced Cell Technology, Inc. Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies
DE60330407D1 (de) 2002-08-23 2010-01-14 Sloan Kettering Inst Cancer Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ITMI20070817A1 (it) * 2007-04-19 2008-10-20 Farmacetika Ltd Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi
JP4208036B1 (ja) * 2007-04-26 2009-01-14 日本新薬株式会社 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物
CN101790377A (zh) * 2007-08-31 2010-07-28 国立大学法人九州大学 抗癌剂导致的末梢神经障碍的预防或减轻剂
US20100310674A1 (en) * 2007-10-30 2010-12-09 Trophos Novel composition for treating the side effects of anticancer treatments
EA201170732A1 (ru) * 2008-12-01 2011-12-30 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Применение алканоил l-карнитина в комбинации с химиотерапевтическими средствами для лечения новообразований
CN102060722B (zh) * 2009-05-01 2014-06-11 常州高新技术产业开发区三维工业技术研究所有限公司 一种含砷化合物及其制备方法和用途
ITPZ20130005A1 (it) * 2013-07-05 2015-01-06 Teodosio Antonio Ferrara Metabolismo energetico e omeostasi
WO2018089231A1 (en) 2016-11-09 2018-05-17 Qiagen Sciences Llc Photoprotective mixtures as imaging reagents in sequencing-by-synthesis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713370A (en) * 1972-11-06 1987-12-15 Felice Stephen L De Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats
IL74449A (en) * 1984-03-01 1988-07-31 Us Commerce Tetrahalo-1,2-cyclohexane-diamino platinum complexes and anti-neoplastic compositions comprising them
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche
ES2235499T3 (es) * 1998-07-30 2005-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena.

Also Published As

Publication number Publication date
CN1708297A (zh) 2005-12-14
BR0316131A (pt) 2005-09-27
EP1562577B1 (de) 2011-10-05
PL379244A1 (pl) 2006-08-07
AU2009201384A1 (en) 2009-05-07
US20060183798A1 (en) 2006-08-17
CA2505937C (en) 2011-07-26
DK1562577T3 (da) 2012-01-23
PT1562577E (pt) 2012-01-12
SI1562577T1 (sl) 2012-01-31
AU2003283807A1 (en) 2004-06-03
AU2003283807B2 (en) 2009-12-03
CY1112399T1 (el) 2015-12-09
AR041947A1 (es) 2005-06-01
CA2505937A1 (en) 2004-05-27
ES2374503T3 (es) 2012-02-17
MXPA05004752A (es) 2005-08-02
US20030199535A1 (en) 2003-10-23
WO2004043454A1 (en) 2004-05-27
TWI362260B (en) 2012-04-21
KR20050075012A (ko) 2005-07-19
EP1562577A1 (de) 2005-08-17
JP2006508958A (ja) 2006-03-16
TW200410683A (en) 2004-07-01

Similar Documents

Publication Publication Date Title
DE60324777D1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
DE60221627D1 (de) Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren
DE60239218D1 (de) Synergistische zusammensetzungen für die behandlung von saatgut
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE602005011279D1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
DE60228713D1 (de) Zusammensetzungen für die behandlung von haaren und/oder kopfhaut
EP1622633A4 (de) Behandlung von t-zell-vermittelten krankheiten
ATE348649T1 (de) Kombinationen von einem hemmer der sterol- absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
DE602004029367D1 (de) Therapeutische und/oder präventive zusammsentzung für periodontale erkrankungen
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
ATE526958T1 (de) Acetyl-l-carnitin für die vorbeugung und/oder behandlung von peripheren neuropathien hervorgerufen durch thalidomid
ATE417616T1 (de) Behandlung von mukositis
ATE427928T1 (de) Fluorobenzamide zur behandlung von alzheimer oder seniler dementia
ATE361745T1 (de) Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
DE602004023721D1 (de) Zusammensetzungen und methoden für die behandlung von herzerkrankungen
ATE446754T1 (de) Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
EP1905452A4 (de) Wirkstoff zur prävention oder behandlung von glaukomen
NO20054913D0 (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
ATE407671T1 (de) Verwendung von sulfonamid-derivate zur herstellung eines medikaments für die vorbeugung oder behandlung von essstörungen
DE60224004D1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE602005014145D1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
EP1791423A4 (de) Zusammensetzungen und verfahren für die behandlung von hyperproliferativen hautkrankheiten
DE602005014141D1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
DE60331359D1 (de) Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1562577

Country of ref document: EP